Dec 05, 2018
Chugai Files Lawsuit against Alexion for Infringement of its Proprietary Antibody Engineering Technology in Japan
| Name of listed company: | Chugai Pharmaceutical Co., Ltd. |
| Code number: | 4519 (1st Section of Tokyo Stock Exchange) |
| Head office: | 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo |
| President & CEO: | Tatsuro Kosaka |
| Inquiries to: | Masahiko Uchida, |
| General Manager, Corporate Communications Dept. | |
| Tel:+81-(0)3-3273-0881 |
Chugai Pharmaceutical Co., Ltd. announced today that it has filed a patent infringement lawsuit at the Tokyo District Court as follows.
- Date of Complaint
December 5, 2018 - Reasons for the Action
Chugai alleges that the anti-C5 antibody ALXN1210 (ravulizumab) product, an investigational drug developed by Alexion Pharma Godo Kaisha (Japan Regional Headquarters), infringes some of its Japan patents (Patent No. 4954326 and No. 6417431) relating to its proprietary antibody engineering technology. Thus, Chugai filed a patent infringement lawsuit against Alexion requesting a judgment that the ALXN1210 product infringes Chugai’s Japan patent and injunctive relief precluding manufacturing and selling of the ALXN1210 product in Japan. - Defendant
- Name:
Alexion Pharma Godo Kaisha - Address:
18-14 Ebisu 1-Chome, Shibuya-ku, Tokyo, JAPAN
- Name:
- Prospects
No changes are expected to be made to Chugai’s financial prospects at this point.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Tomoko Shimizu
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Toshiya Sasai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
